Optimizing high throughput antibody purification by using continuous chromatography media.
Identifieur interne : 000812 ( Main/Exploration ); précédent : 000811; suivant : 000813Optimizing high throughput antibody purification by using continuous chromatography media.
Auteurs : Rebecca E. Butcher [Australie] ; Genevieve Martin-Roussety [Australie] ; Rebecca A. Bradford [Australie] ; Andrea Tester [Australie] ; Catherine Owczarek [Australie] ; Matthew P. Hardy [Australie] ; Chao-Guang Chen [Australie] ; Georgina Sansome [Australie] ; Louis J. Fabri [Australie] ; Peter M. Schmidt [Allemagne]Source :
- Protein expression and purification [ 1096-0279 ] ; 2019.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (composition chimique), Anticorps monoclonaux (génétique), Cellules cultivées (MeSH), Chromatographie d'affinité (MeSH), Humains (MeSH), Protéine A staphylococcique (composition chimique), Protéines de fusion recombinantes (composition chimique), Protéines de fusion recombinantes (génétique), Robotique (MeSH), Tests de criblage à haut débit (méthodes), Transfection (MeSH).
- MESH :
- composition chimique : Anticorps monoclonaux, Protéine A staphylococcique, Protéines de fusion recombinantes.
- génétique : Anticorps monoclonaux, Protéines de fusion recombinantes.
- méthodes : Tests de criblage à haut débit.
- Cellules cultivées, Chromatographie d'affinité, Humains, Robotique, Transfection.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (chemistry), Antibodies, Monoclonal (genetics), Cells, Cultured (MeSH), Chromatography, Affinity (MeSH), High-Throughput Screening Assays (methods), Humans (MeSH), Recombinant Fusion Proteins (chemistry), Recombinant Fusion Proteins (genetics), Robotics (MeSH), Staphylococcal Protein A (chemistry), Transfection (MeSH).
- MESH :
- chemical , chemistry : Antibodies, Monoclonal, Recombinant Fusion Proteins, Staphylococcal Protein A.
- chemical , genetics : Antibodies, Monoclonal, Recombinant Fusion Proteins.
- methods : High-Throughput Screening Assays.
- Cells, Cultured, Chromatography, Affinity, Humans, Robotics, Transfection.
Abstract
The ability to engineer monoclonal antibodies (mAbs) with high specificity made mAbs the fastest growing segment in the drug market. mAbs represent 8 of the top 20 selling drugs with combined sales of more than 57 billion US$ per year. The ability to purify large numbers of mAbs with sufficient yields for initial screening campaigns has direct impact on the timelines of a project. Automated liquid handling (ALH)-based mAb purification platforms have been used to facilitate the production of large numbers of mAbs. However, the ongoing pressure to de-risk potential lead molecules at an early development stage by including bio-physical characterization of mAbs has further increased the demand to produce sufficient quantities from limited sample volumes. A bottleneck so far has been the limited dynamic binding capacity of these systems, which is partly due to the binding properties of commonly used Protein A affinity matrices. The present publication suggests that by using a Protein A matrix optimized for continuous chromatography applications the yields of ALH-based but also standard lab-scale mAb purifications can be significantly increased without the need to change established protocols.
DOI: 10.1016/j.pep.2019.03.011
PubMed: 30917921
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimizing high throughput antibody purification by using continuous chromatography media.</title><author><name sortKey="Butcher, Rebecca E" sort="Butcher, Rebecca E" uniqKey="Butcher R" first="Rebecca E" last="Butcher">Rebecca E. Butcher</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Martin Roussety, Genevieve" sort="Martin Roussety, Genevieve" uniqKey="Martin Roussety G" first="Genevieve" last="Martin-Roussety">Genevieve Martin-Roussety</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Bradford, Rebecca A" sort="Bradford, Rebecca A" uniqKey="Bradford R" first="Rebecca A" last="Bradford">Rebecca A. Bradford</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Tester, Andrea" sort="Tester, Andrea" uniqKey="Tester A" first="Andrea" last="Tester">Andrea Tester</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Owczarek, Catherine" sort="Owczarek, Catherine" uniqKey="Owczarek C" first="Catherine" last="Owczarek">Catherine Owczarek</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Hardy, Matthew P" sort="Hardy, Matthew P" uniqKey="Hardy M" first="Matthew P" last="Hardy">Matthew P. Hardy</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Chao Guang" sort="Chen, Chao Guang" uniqKey="Chen C" first="Chao-Guang" last="Chen">Chao-Guang Chen</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Sansome, Georgina" sort="Sansome, Georgina" uniqKey="Sansome G" first="Georgina" last="Sansome">Georgina Sansome</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Fabri, Louis J" sort="Fabri, Louis J" uniqKey="Fabri L" first="Louis J" last="Fabri">Louis J. Fabri</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, 45 Poplar Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, 45 Poplar Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Schmidt, Peter M" sort="Schmidt, Peter M" uniqKey="Schmidt P" first="Peter M" last="Schmidt">Peter M. Schmidt</name><affiliation wicri:level="3"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia; CSL Behring GmbH, R&D, Emil-von-Behring Str. 76, Marburg, 35041, Germany. Electronic address: Peter.Schmidt@cslbehring.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia; CSL Behring GmbH, R&D, Emil-von-Behring Str. 76, Marburg, 35041</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30917921</idno><idno type="pmid">30917921</idno><idno type="doi">10.1016/j.pep.2019.03.011</idno><idno type="wicri:Area/Main/Corpus">000972</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000972</idno><idno type="wicri:Area/Main/Curation">000972</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000972</idno><idno type="wicri:Area/Main/Exploration">000972</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Optimizing high throughput antibody purification by using continuous chromatography media.</title><author><name sortKey="Butcher, Rebecca E" sort="Butcher, Rebecca E" uniqKey="Butcher R" first="Rebecca E" last="Butcher">Rebecca E. Butcher</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Martin Roussety, Genevieve" sort="Martin Roussety, Genevieve" uniqKey="Martin Roussety G" first="Genevieve" last="Martin-Roussety">Genevieve Martin-Roussety</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Bradford, Rebecca A" sort="Bradford, Rebecca A" uniqKey="Bradford R" first="Rebecca A" last="Bradford">Rebecca A. Bradford</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Tester, Andrea" sort="Tester, Andrea" uniqKey="Tester A" first="Andrea" last="Tester">Andrea Tester</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Owczarek, Catherine" sort="Owczarek, Catherine" uniqKey="Owczarek C" first="Catherine" last="Owczarek">Catherine Owczarek</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Hardy, Matthew P" sort="Hardy, Matthew P" uniqKey="Hardy M" first="Matthew P" last="Hardy">Matthew P. Hardy</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Chao Guang" sort="Chen, Chao Guang" uniqKey="Chen C" first="Chao-Guang" last="Chen">Chao-Guang Chen</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Sansome, Georgina" sort="Sansome, Georgina" uniqKey="Sansome G" first="Georgina" last="Sansome">Georgina Sansome</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Fabri, Louis J" sort="Fabri, Louis J" uniqKey="Fabri L" first="Louis J" last="Fabri">Louis J. Fabri</name><affiliation wicri:level="1"><nlm:affiliation>CSL Limited, 45 Poplar Road, Parkville, Victoria, 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSL Limited, 45 Poplar Road, Parkville, Victoria, 3010</wicri:regionArea><wicri:noRegion>3010</wicri:noRegion></affiliation></author><author><name sortKey="Schmidt, Peter M" sort="Schmidt, Peter M" uniqKey="Schmidt P" first="Peter M" last="Schmidt">Peter M. Schmidt</name><affiliation wicri:level="3"><nlm:affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia; CSL Behring GmbH, R&D, Emil-von-Behring Str. 76, Marburg, 35041, Germany. Electronic address: Peter.Schmidt@cslbehring.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia; CSL Behring GmbH, R&D, Emil-von-Behring Str. 76, Marburg, 35041</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author></analytic><series><title level="j">Protein expression and purification</title><idno type="eISSN">1096-0279</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (chemistry)</term><term>Antibodies, Monoclonal (genetics)</term><term>Cells, Cultured (MeSH)</term><term>Chromatography, Affinity (MeSH)</term><term>High-Throughput Screening Assays (methods)</term><term>Humans (MeSH)</term><term>Recombinant Fusion Proteins (chemistry)</term><term>Recombinant Fusion Proteins (genetics)</term><term>Robotics (MeSH)</term><term>Staphylococcal Protein A (chemistry)</term><term>Transfection (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (composition chimique)</term><term>Anticorps monoclonaux (génétique)</term><term>Cellules cultivées (MeSH)</term><term>Chromatographie d'affinité (MeSH)</term><term>Humains (MeSH)</term><term>Protéine A staphylococcique (composition chimique)</term><term>Protéines de fusion recombinantes (composition chimique)</term><term>Protéines de fusion recombinantes (génétique)</term><term>Robotique (MeSH)</term><term>Tests de criblage à haut débit (méthodes)</term><term>Transfection (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Recombinant Fusion Proteins</term><term>Staphylococcal Protein A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Protéine A staphylococcique</term><term>Protéines de fusion recombinantes</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Protéines de fusion recombinantes</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>High-Throughput Screening Assays</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Tests de criblage à haut débit</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cells, Cultured</term><term>Chromatography, Affinity</term><term>Humans</term><term>Robotics</term><term>Transfection</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules cultivées</term><term>Chromatographie d'affinité</term><term>Humains</term><term>Robotique</term><term>Transfection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The ability to engineer monoclonal antibodies (mAbs) with high specificity made mAbs the fastest growing segment in the drug market. mAbs represent 8 of the top 20 selling drugs with combined sales of more than 57 billion US$ per year. The ability to purify large numbers of mAbs with sufficient yields for initial screening campaigns has direct impact on the timelines of a project. Automated liquid handling (ALH)-based mAb purification platforms have been used to facilitate the production of large numbers of mAbs. However, the ongoing pressure to de-risk potential lead molecules at an early development stage by including bio-physical characterization of mAbs has further increased the demand to produce sufficient quantities from limited sample volumes. A bottleneck so far has been the limited dynamic binding capacity of these systems, which is partly due to the binding properties of commonly used Protein A affinity matrices. The present publication suggests that by using a Protein A matrix optimized for continuous chromatography applications the yields of ALH-based but also standard lab-scale mAb purifications can be significantly increased without the need to change established protocols.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30917921</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0279</ISSN><JournalIssue CitedMedium="Internet"><Volume>159</Volume><PubDate><Year>2019</Year><Month>07</Month></PubDate></JournalIssue><Title>Protein expression and purification</Title><ISOAbbreviation>Protein Expr Purif</ISOAbbreviation></Journal><ArticleTitle>Optimizing high throughput antibody purification by using continuous chromatography media.</ArticleTitle><Pagination><MedlinePgn>75-82</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1046-5928(19)30148-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pep.2019.03.011</ELocationID><Abstract><AbstractText>The ability to engineer monoclonal antibodies (mAbs) with high specificity made mAbs the fastest growing segment in the drug market. mAbs represent 8 of the top 20 selling drugs with combined sales of more than 57 billion US$ per year. The ability to purify large numbers of mAbs with sufficient yields for initial screening campaigns has direct impact on the timelines of a project. Automated liquid handling (ALH)-based mAb purification platforms have been used to facilitate the production of large numbers of mAbs. However, the ongoing pressure to de-risk potential lead molecules at an early development stage by including bio-physical characterization of mAbs has further increased the demand to produce sufficient quantities from limited sample volumes. A bottleneck so far has been the limited dynamic binding capacity of these systems, which is partly due to the binding properties of commonly used Protein A affinity matrices. The present publication suggests that by using a Protein A matrix optimized for continuous chromatography applications the yields of ALH-based but also standard lab-scale mAb purifications can be significantly increased without the need to change established protocols.</AbstractText><CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Butcher</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Roussety</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradford</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tester</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owczarek</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chao-Guang</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sansome</LastName><ForeName>Georgina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabri</LastName><ForeName>Louis J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>CSL Limited, 45 Poplar Road, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>CSL Limited, BIO21 Institute, 30 Flemington Road, Parkville, Victoria, 3010, Australia; CSL Behring GmbH, R&D, Emil-von-Behring Str. 76, Marburg, 35041, Germany. Electronic address: Peter.Schmidt@cslbehring.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Protein Expr Purif</MedlineTA><NlmUniqueID>9101496</NlmUniqueID><ISSNLinking>1046-5928</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013205">Staphylococcal Protein A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002846" MajorTopicYN="N">Chromatography, Affinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012371" MajorTopicYN="N">Robotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013205" MajorTopicYN="N">Staphylococcal Protein A</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antibody</Keyword><Keyword MajorTopicYN="Y">Continuous chromatography</Keyword><Keyword MajorTopicYN="Y">High throughput</Keyword><Keyword MajorTopicYN="Y">Liquid handling</Keyword><Keyword MajorTopicYN="Y">Robotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>03</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>03</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30917921</ArticleId><ArticleId IdType="pii">S1046-5928(19)30148-2</ArticleId><ArticleId IdType="doi">10.1016/j.pep.2019.03.011</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li></country><region><li>District de Giessen</li><li>Hesse (Land)</li></region><settlement><li>Marbourg</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Butcher, Rebecca E" sort="Butcher, Rebecca E" uniqKey="Butcher R" first="Rebecca E" last="Butcher">Rebecca E. Butcher</name></noRegion><name sortKey="Bradford, Rebecca A" sort="Bradford, Rebecca A" uniqKey="Bradford R" first="Rebecca A" last="Bradford">Rebecca A. Bradford</name><name sortKey="Chen, Chao Guang" sort="Chen, Chao Guang" uniqKey="Chen C" first="Chao-Guang" last="Chen">Chao-Guang Chen</name><name sortKey="Fabri, Louis J" sort="Fabri, Louis J" uniqKey="Fabri L" first="Louis J" last="Fabri">Louis J. Fabri</name><name sortKey="Hardy, Matthew P" sort="Hardy, Matthew P" uniqKey="Hardy M" first="Matthew P" last="Hardy">Matthew P. Hardy</name><name sortKey="Martin Roussety, Genevieve" sort="Martin Roussety, Genevieve" uniqKey="Martin Roussety G" first="Genevieve" last="Martin-Roussety">Genevieve Martin-Roussety</name><name sortKey="Owczarek, Catherine" sort="Owczarek, Catherine" uniqKey="Owczarek C" first="Catherine" last="Owczarek">Catherine Owczarek</name><name sortKey="Sansome, Georgina" sort="Sansome, Georgina" uniqKey="Sansome G" first="Georgina" last="Sansome">Georgina Sansome</name><name sortKey="Tester, Andrea" sort="Tester, Andrea" uniqKey="Tester A" first="Andrea" last="Tester">Andrea Tester</name></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Schmidt, Peter M" sort="Schmidt, Peter M" uniqKey="Schmidt P" first="Peter M" last="Schmidt">Peter M. Schmidt</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000812 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000812 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30917921
|texte= Optimizing high throughput antibody purification by using continuous chromatography media.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30917921" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |